Trinity Biotech (NASDAQ:TRIB) Earns Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report published on Wednesday. The firm issued a buy rating on the stock.

Trinity Biotech Price Performance

Shares of Trinity Biotech stock opened at $1.83 on Wednesday. The company has a market capitalization of $13.94 million, a price-to-earnings ratio of -0.58 and a beta of 1.21. Trinity Biotech has a 12-month low of $1.79 and a 12-month high of $5.50. The firm’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $2.24.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Thursday, April 4th. The company reported ($0.68) earnings per share (EPS) for the quarter. The business had revenue of $13.43 million for the quarter. On average, sell-side analysts expect that Trinity Biotech will post -1.5 earnings per share for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.